AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 11136273
Drug: Lactobacillus GG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lactobacillus GG (LGG) ingestion for 5 days before indometacin administration
Trial: 11136273
Drug: Heat-killed LGG
RxNorm normalized name: heather pollen extract
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Heat-killed LGG ingestion for 5 days before indometacin administration
Trial: 11136273
Drug: Indometacin administration
RxNorm normalized name: indometacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indometacin administration
Trial: 8201379
Drug: ESHAP regimen
RxNorm normalized name: Anacin Aspirin Regimen Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ESHAP regimen (VP‐16 40 mg/m2/d for 4 days, methylprednisolone 500 mg IV daily for 5 days, Ara‐C 2 g/m2 IV on day 5, with cisplatin 25 mg/m2 IV for 4 days)
Trial: 3606083
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rimantadine tablet (single dose) followed by 100 mg twice a day for 10 days (regimen 1)
Trial: 3606083
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg rimantadine tablet (single dose) followed by 100 mg once a day for 10 days (regimen 2)
Trial: 28332374
Drug: Dexmedetomidine (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Dexmedetomidine (1 μg/kg) with 0.2% ropivacaine (0.2 mL/kg)
Trial: 28332374
Drug: Fentanyl (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Fentanyl (1 μg/kg) with 0.2% ropivacaine (0.2 mL/kg)
Trial: 26039935
Drug: Lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 20 μg with sulfonylureas
Trial: 26039935
Drug: Lixisenatide 20
RxNorm normalized name: lixisenatide 20 mcg/0.2 mL subcutaneous solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Lixisenatide 20 μg without sulfonylureas
Trial: 20141706
Drug: 30 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 30 mg/d of lisdexamfetamine dimesylate
Trial: 20141706
Drug: 50 mg/d
RxNorm normalized name: infigratinib phosphate 50 mg/day (25 mg x 2) ORAL CAPSULE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 50 mg/d of lisdexamfetamine dimesylate
Trial: 20141706
Drug: 70 mg/d
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 70 mg/d of lisdexamfetamine dimesylate
Trial: 17107241
Drug: Haloperidol (5.4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Haloperidol (5.4 mg/day)
Trial: 16062094
Drug: Risperidone (4
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone (4 mg/day)
Trial: 17107241
Drug: Olanzapine (15.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Olanzapine (15.3 mg/day)
Trial: 15116860
Drug: Early invasive
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early invasive approach with glycoprotein IIb/IIIa receptor blockers
Trial: 9474610
Drug: Topical anesthetic
RxNorm normalized name: Topical anesthetic
DrugBank: Benzocaine (DB01086)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Topical anesthetic application
Trial: 9474610
Drug: Phentolamine infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Phentolamine infusion
Trial: 8701596
Drug: Purified influenza
RxNorm normalized name: RAYON,PURIFIED
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Purified influenza virus (N2) neuraminidase vaccine (NAV)
Trial: 8701596
Drug: Conventional trivalent
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Conventional trivalent influenza vaccine, Fluogen (Parke‐Davis)
Trial: 27373
Drug: Mianserin 3
RxNorm normalized name: mianserin 30 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mianserin 3 X 10 mg daily or 3 X 20 mg daily
Trial: 31258920
Drug: Intermittent treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent treatment (three times a week) with clarithromycin, rifampicin, and ethambutol for 1 year
Trial: 31258920
Drug: Daily treatment
RxNorm normalized name: BENZOYL PEROXIDE 2.5 g in 100 g TOPICAL GEL [Acne defense Daily Treatment Serum Merle Norman]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Daily treatment with clarithromycin, rifampicin, and ethambutol for 1 year
Trial: 26926538
Drug: Tamsulosin (0.01
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tamsulosin (0.01 mg/kg once daily) as adjunctive therapy after shock wave lithotripsy
Trial: 24419109
Drug: Not applicable
RxNorm normalized name: AIR 1000 mL in 1 L NOT APPLICABLE GAS
DrugBank: Urea (DB03904)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Not applicable (completion of therapy)
Trial: 22664978
Drug: Ropivacaine 0.375%
RxNorm normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.375% 10 mL
Trial: 22664978
Drug: Ropivacaine 0.375%
RxNorm normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.375% 20 mL
Trial: 22664978
Drug: Ropivacaine 0.375%
RxNorm normalized name: ROPivacaine 0.375%-NaCl 0.9% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.375% 40 mL
Trial: 22664978
Drug: Ropivacaine 0.75%
RxNorm normalized name: ROPivacaine 0.75% injectable solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ropivacaine 0.75% 5 mL
Trial: 19619331
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids (budesonide)
Trial: 12442238
Drug: Intravenous opiate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous opiate analgesia
Trial: 9660383
Drug: Chlorthalidone (12.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Chlorthalidone (12.5 to 25 mg/d) with step-up to atenolol (25.0 to 50.0 mg/d) or reserpine (0.05 to 0.10 mg/d)
Trial: 27039945
Drug: Combined therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined therapy (rosuvastatin 10 mg/day, candesartan 16 mg/day, hydrochlorothiazide 12.5 mg/day)
Trial: 23303315
Drug: Folic acid-iron
RxNorm normalized name: folic acid / iron carbonyl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Folic acid-iron (30 mg)
Trial: 23303315
Drug: Daily folic
RxNorm normalized name: Folic Acid
DrugBank: Folic acid (DB00158)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Daily folic acid (400 μg)
Trial: 12534314
Drug: Controlled-release preparation
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Controlled-release preparation of VPA
Trial: 8729154
Drug: Multiple daily
RxNorm normalized name: Multivitamin Oral Tablet [MULTIPLE DAILY W/BETA]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multiple daily injections (MDIs)
Trial: 1314910
Drug: No radiation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No radiation therapy (Control)
Trial: 20223500
Drug: TNF-alpha inhibitors
FDA approved: no
EMA approved: no
PMDA approved: no
Description: TNF-alpha inhibitors
Trial: 20223500
Drug: Other biologic
RxNorm normalized name: Ether
DrugBank: Diethyl ether (DB13598)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Other biologic agents
Trial: 16756149
Drug: Inhaled corticosteroids
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Inhaled corticosteroids and long acting beta2-agonists
Trial: 1797953
Drug: 3 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 3 g/day of Andrographis paniculata
Trial: 1797953
Drug: 6 g/day
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 6 g/day of Andrographis paniculata
Trial: 29522174
Drug: Enzalutamide 160
RxNorm normalized name: Enzalutamide
DrugBank: Enzalutamide (DB08899)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Enzalutamide 160 mg
Trial: 23767865
Drug: Salacia extracts
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Salacia extracts (500 mg/day)
Trial: 17765214
Drug: Verbal 'Stories'
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Verbal 'Stories' task with concurrent executive function tasks
Trial: 16794882
Drug: Individual approach
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual approach in the care of people with dementia; specific details on dosage and duration not available.
Trial: 16794882
Drug: Individual everyday
RxNorm normalized name: chloroxylenol
DrugBank: Chloroxylenol (DB11121)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Individual everyday situations for residents; specific details on dosage and duration not available.
Trial: 16794882
Drug: Communication between
RxNorm normalized name: cocklebur pollen extract
DrugBank: Xanthium strumarium pollen (DB10356)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Communication between nurses and residents; specific details on dosage and duration not available.
Trial: 16794882
Drug: Personal attention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Personal attention from nurses; specific details on dosage and duration not available.
Trial: 11189683
Drug: Digital rectal
RxNorm normalized name: BD Thermometer Digital Rectal (obsolete)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Digital rectal examination and blood test for prostate-specific antigen (PSA) for prostate cancer
Trial: 9314997
Drug: 50-125 mL
RxNorm normalized name: tezacaftor
DrugBank: Tezacaftor (DB11712)
FDA approved: yes
EMA approved: yes
PMDA approved: no
Description: 50-125 mL of 60% nonionic contrast material pushed with 50 mL of saline
Trial: 9314997
Drug: 125 mL
RxNorm normalized name: 125 ML argatroban 1 MG/ML Injection
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 125 mL of 60% nonionic contrast material administered alone
Trial: 28597693
Drug: Modified constraint-induced
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modified constraint-induced movement therapy + mental practice
Trial: 12415196
Drug: 5‐FU/LEV, weekly,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 5‐FU/LEV, weekly, 12 months
Trial: 10503821
Drug: Omeprazole-metronidazole-clarithromycin treatment
RxNorm normalized name: Clarithromycin
DrugBank: Clarithromycin (DB01211)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Omeprazole-metronidazole-clarithromycin treatment
Trial: 8565748
Drug: High-dose interferon
RxNorm normalized name: interferon-beta
DrugBank: Human interferon beta (DB14999)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-dose interferon therapy
Trial: 7307591
Drug: Indomethacin therapy
RxNorm normalized name: Indomethacin
DrugBank: Indomethacin (DB00328)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Indomethacin therapy
Trial: 27744141
Drug: Tocilizumab (8
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tocilizumab (8 mg/kg every 4 weeks plus DMARDs)
Trial: 25623430
Drug: Antigen carbohydrate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antigen carbohydrate 125-guided therapy
Trial: 16037107
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol moistened with 3 ml of 5% acetic acid (group A, n = 33)
Trial: 16037107
Drug: Intravaginal misoprostol
RxNorm normalized name: Misoprostol
DrugBank: Misoprostol (DB00929)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Intravaginal misoprostol moistened with 3 ml of saline (group B, n = 33)
Trial: 12074357
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of Candesartan 16 mg and Felodipine 5 mg
Trial: 10583039
Drug: Grape juice
RxNorm normalized name: grape juice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Grape juice (200 ml)
Trial: 30666826
Drug: Tofacitinib 5
RxNorm normalized name: tofacitinib 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tofacitinib 5 mg or 10 mg twice daily plus MTX
Trial: 19057387
Drug: Cream intake
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cream intake (highest quintile)
Trial: 19057387
Drug: Total dairy,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Total dairy, low-fat milk, sour milk, cheese, ice cream, butter intake
Trial: 9610927
Drug: 4% BCAA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% BCAA solution
Trial: 9610927
Drug: 4% amino
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 4% amino acid solution
Trial: 7821128
Drug: Sulfonylurea (glyburide,
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sulfonylurea (glyburide, G)
Trial: 7821128
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (M/G, G/M, MGH)
Trial: 7821128
Drug: Single-drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Single-drug therapy (M or G)
Trial: 7821128
Drug: Low-dose primary
RxNorm normalized name: ethinyl estradiol
DrugBank: Ethinylestradiol (DB00977)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Low-dose primary combination (MGL)
Trial: 7821128
Drug: Glyburide alone
RxNorm normalized name: Glyburide
DrugBank: Glyburide (DB01016)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Glyburide alone (G)
Trial: 7821128
Drug: Combination therapy
RxNorm normalized name: REGN10933+REGN10987 combination therapy
DrugBank: Anti-SARS-CoV-2 REGN-COV2 (DB15691)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination therapy (M and G)
Trial: 7821128
Drug: Overall drug
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Overall drug safety
Trial: 3270508
Drug: Hydroxyurea (500
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Hydroxyurea (500 mg orally every 4 hours for 3 days)
Trial: 3270508
Drug: Etoposide (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etoposide (100 mg/m2 per day by continuous infusion for 3 days)
Trial: 3270508
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of hydroxyurea and etoposide (fixed molar ratio of 58.9:1)
Trial: 24534036
Drug: N alpha
RxNorm normalized name: Lutropin alpha
DrugBank: Lutropin alfa (DB00044)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: N alpha methyl histamine (1 to 3 ug twice a week)
Trial: 23437548
Drug: Vaccine candidate
RxNorm normalized name: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
DrugBank: FINLAY-FR-1 (DB16524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine candidate (live attenuated oral Vibrio cholerae Ol El Tor, Ogawa strain 638)
Trial: 23437548
Drug: Vaccine candidate
RxNorm normalized name: FINLAY-FR-1 anti-SARS-CoV-2 vaccine candidate
DrugBank: FINLAY-FR-1 (DB16524)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vaccine candidate
Trial: 15681602
Drug: Radiotherapy +
RxNorm normalized name: sodium fluoride
DrugBank: Sodium fluoride (DB09325)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Radiotherapy + Endocrine Therapy
Trial: 15681602
Drug: Endocrine Therapy
RxNorm normalized name: ENDOCRINE THERAPY
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Endocrine Therapy Alone
Trial: 21149918
Drug: Once-daily lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily lamivudine
Trial: 21149918
Drug: Once-daily abacavir
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily abacavir
Trial: 21149918
Drug: Twice-daily lamivudine
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily lamivudine
Trial: 21149918
Drug: Twice-daily abacavir
RxNorm normalized name: clindamycin
DrugBank: Clindamycin (DB01190)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Twice-daily abacavir
Trial: 21149918
Drug: Once-daily lamivudine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Once-daily lamivudine and abacavir
Trial: 11254911
Drug: No lipid
RxNorm normalized name: guggul lipids
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No lipid lowering therapy
Trial: 9647153
Drug: Diclofenac (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Diclofenac (100 mg suppositories)
Trial: 8090921
Drug: Gadoteridol at
RxNorm normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadoteridol at standard dose (0.1 mmol/kg)
Trial: 8090921
Drug: Gadoteridol at
RxNorm normalized name: Gadoteridol
DrugBank: Gadoteridol (DB00597)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Gadoteridol at triple dose (0.3 mmol/kg)
Trial: 8090921
Drug: Both doses
RxNorm normalized name: Bothrops atrox venom
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Both doses of gadoteridol
Trial: 2531389
Drug: Propranolol therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Propranolol therapy (n = 26 after exclusions)
Trial: 23723278
Drug: Operative treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Operative treatment (fixation of the clavicular fracture)
Trial: 17943677
Drug: Remote administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote administration of the Functional Reach Test (FRT)
Trial: 17943677
Drug: Remote administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Remote administration of the European Stroke Scale (ESS)
Trial: 17943677
Drug: Face-to-face administration
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face administration of the Functional Reach Test (FRT)
Trial: 17943677
Drug: Face-to-face administration
RxNorm normalized name: FACE SHIELD
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Face-to-face administration of the European Stroke Scale (ESS)
Trial: 11340701
Drug: Intranasal beclomethasone
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intranasal beclomethasone dipropionate (BDP) 400 micrograms/day
Trial: 9272245
Drug: Estradiol transdermal
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal patch (Dermestril) with 25 micrograms/day
Trial: 9272245
Drug: Estradiol transdermal
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal patch (Dermestril) with 50 micrograms/day
Trial: 9272245
Drug: Estradiol transdermal
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal patch (Dermestril) with 100 micrograms/day
Trial: 9272245
Drug: Estradiol transdermal
RxNorm normalized name: Estradiol Transdermal System
DrugBank: Estradiol (DB00783)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Estradiol transdermal patch (Dermestril)
Trial: 21920711
Drug: SSRI monotherapy
RxNorm normalized name: Adoptive immunotherapy agent CTL019
DrugBank: Tisagenlecleucel (DB13881)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: SSRI monotherapy (escitalopram plus placebo)
Trial: 21920711
Drug: Combination antidepressant
RxNorm normalized name: ANTIDEPRESSANTS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination antidepressant medication (bupropion-sustained release plus escitalopram or venlafaxine-extended release plus mirtazapine)
Trial: 15309376
Drug: LY354740 (100
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY354740 (100 mg)
Trial: 15309376
Drug: LY354740 (400
FDA approved: no
EMA approved: no
PMDA approved: no
Description: LY354740 (400 mg)
Trial: 10389719
Drug: 10-cm2 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10-cm2 patch of 0.025 mg estradiol and 0.125 mg norethisterone acetate
Trial: 10389719
Drug: 20-cm2 patch
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 20-cm2 patch of 0.05 mg estradiol and 0.25 mg norethisterone acetate
Trial: 10389719
Drug: Oral HRT
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral HRT (2 mg estradiol and 1 mg norethisterone acetate)
Trial: 31758571
Drug: Sequential therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential therapy (10 days of rabeprazole, clarithromycin, amoxycillin, and tinidazole; 60 pills, cost US$10)
Trial: 31758571
Drug: Concomitant therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Concomitant therapy (14 days of rabeprazole, clarithromycin, amoxycillin, and tinidazole; 140 pills, cost US$23)
Trial: 29665833
Drug: Bioactive vitamin
RxNorm normalized name: Vitamin A
DrugBank: Vitamin A (DB00162)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bioactive vitamin D (calcitriol) added to RAAS inhibition treatment using ACEI or ARB
Trial: 28498184
Drug: ART failure
RxNorm normalized name: INVESTIGATIONAL CONGESTIVE HEART FAILURE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ART failure (HIVRNA ≥1000 copies/ml)
Trial: 25748549
Drug: Exercise programme
RxNorm normalized name: Immunoglobulin G4, anti-programmed cell death protein 1 (PDCD1) (humanized clone ABT1 gamma4-chain), disulfide with humanized clone ABT1 kappa-chain, dimer
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Exercise programme (six sessions of strengthening and stretching exercises with a hand therapist, daily home exercises)
Trial: 18067975
Drug: Medication (tianeptine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Medication (tianeptine or fluoxetine) + Psychotherapy (supportive, cognitive-behavioral, or psychodynamic)
Trial: 12676739
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg, orally) with placebo
Trial: 12676739
Drug: Furosemide (40
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (40 mg, orally) with losartan (50 mg, orally)
Trial: 1506604
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g glucose ingestion in late pregnant women
Trial: 1506604
Drug: 100 g
RxNorm normalized name: Berri-Freez 4.5 GM per 100 GM
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 g glucose ingestion in nonpregnant women